viatris semaglutide gets USPTO to review Novo Nordisk patent for Semaglutide is similar to a natural hormone in your body (incretin) Triple-strength' Wegovy injection gets MHRA

The researchers found that an older diabetes drug, which is a precursor to Ozempic, may have a protective effect on the nervous system in people living with early-stage Parkinson's disease

The 2022 ADA/EASD consensus recommends a patient-centred approach for the management of T2D that considers cardiovascular disease (CVD) history, weight, hypoglycaemic risk, treatment cost and other patient-related factors

Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes

Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptyingpreclinical evidence